UC consortium launches first clinical trial using CRISPR to correct sickle cell gene

(University of California - San Francisco) Scientists at UC San Francisco, UC Berkeley and UCLA have received U.S. Food and Drug Administration approval to jointly launch an early phase, first-in-human clinical trial of a CRISPR gene correction therapy in patients with sickle cell disease using the patient's own blood-forming stem cells.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news